By Karen Roman MOBILion Systems announced it is presenting the latest features of its mass spectrometry platform, MOBIE EyeOn 2.3, at the 72nd American Society for Mass Spectrometry (ASMS) Conference in California. The latest software introduces new capabilities and streamlines...

By Daniella Parra Sparrow Pharmaceuticals said its HSD-1 inhibitor, clofutriben (SPI-62), normalized urine free cortisol in over 60% of patients with endogenous Cushing’s syndrome without significantly lowering serum cortisol, minimizing the risk of adrenal insufficiency. Traditional EnCS treatments require careful...

By Daniella Parra Creyon Bio, Inc. said it is using AI to engineer treatments for rare and common diseases. The platform’s ability to predict and mitigate safety concerns signifies a promising advancement as they customized a treatment within a year,...

By Karen Roman FIGS, Inc. (NYSE: FIGS), a global healthcare apparel brand, said net revenue was at the upper end of expectations and exceeded the outlook in the first quarter. The company reported a 0.8% decrease year over year in...

By Daniella Parra Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, said its net loss was $5.4 million for the three months ended March 31, compared to $6.2 million in 2023. The company said an experimental drug to improve...

  By Daniella Parra Creyon Bio, Inc. and Cajal Neuroscience have teamed up to develop therapies for neurodegenerative diseases, they said. The companies aim to accelerate the development of treatments for common neurodegenerative disorders, engineering medicines using human data and...

By Karen Roman Agendia, Inc.’s BluePrint was recently included in the latest version of German Gynecological Oncology Group (AGO) guidelines for chemotherapy decision making. AGO is comprised of gynecological oncologists specialized in breast cancer and interdisciplinary members focused on pathology,...

By Daniella Parra Gameto, a female-led biotechnology firm, said it received tentative FDA approval to move to Phase 3 trials for Fertilo, a pivotal step towards Biologic License Application approval, the company said. The primary efficacy endpoint will assess pregnancy...

By Karen Roman Orthobond Corp. said the Food and Drug Administration approved its request to market Ostaguard, an antibacterial surface treatment used on permanent spine implants. This is the first time the FDA granted approval for a medical device with...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company, announced it signed an agreement with global pharmaceutical and biotech partner Lonza. The collaboration includes the manufacturing of sabirnetug (ACU193), an antibody for the treatment of Alzheimer’s disease...